CHIEF EXECUTIVE OFFICER
Flemming Ørnskov, M.D., MPH joined Galderma as Chief Executive Officer in October 2019. He leads the company’s corporate-wide vision and strategy and new business building, shaping and stewarding the growth of a world-class organization.
Prior to joining Galderma, Flemming served as CEO of Shire plc from 2013 to 2019. Earlier in his career he held a number of leadership positions in the pharmaceutical industry, including: Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer; Global President, Pharmaceuticals and OTC at Bausch & Lomb Inc.; first Chairman then CEO of Lifecycle Pharma A/S (now Veloxis); President and CEO of Ikaria Inc.; President of Ophthalmology at Novartis; and various roles of increasing responsibility at Merck & Co. He is currently a non-Executive Chairman of Waters Corporation.
Flemming qualified as a Doctor of Medicine at the University of Copenhagen Medical School, gained a Master of Public Health (MPH) at Harvard University School of Public Health and an MBA from INSEAD.